secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001193125-23-062068
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics reports FY2022 net loss $250.2M, SER-109 PDUFA date April 26, 2023
--------------------------------------------------------------------------------

- FY2022 net loss $250.2M vs $65.6M in FY2021; Q4 net loss $68.8M vs $50.0M.
- Cash & equivalents $181.3M at Dec 31, 2022, down from $291.2M at end of 2021.
- SER-109 BLA under FDA priority review with PDUFA target action date April 26, 2023; commercial launch anticipated soon after.
- SER-155 Phase 1b: cohort 2 enrollment ongoing; initial safety/pharmacology data from cohort 1 expected May 2023.
- Pending FDA approval, Seres expects $125M milestone payment from Nestlé Health Science.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523062068/0001193125-23-062068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523062068/d448387d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-062068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer